Insulinomas are the second most common neuroendocrine tumors of the functional GEP tract (GEP-NETs) in MEN1 after gastrinomas, affecting approximately 10–15% of patients with MEN1, and they often develop in patients aged 10–39 years, earlier than sporadic insulinomas [4]. Currently, surgical resection is the only curative treatment, and the choice of surgical method is associated with a short-term cure for hypoglycemia and the risk of long-term recurrence. This evidence concerns the gene MEN1 and pancreatic insulinoma.